J. Han

发表

Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.

H. S. Kim, S. H. Lee, M. Shin, 1999, Cancer research.

Does the age affect the efficacy of angiogenesis inhibitors in ovarian cancer? A meta-analysis of randomized controlled trials.

N. Li, J. Han, Congxiu Miao, 2017, European review for medical and pharmacological sciences.

A retrospective study of different treatments of limited-stage small-cell esophageal carcinoma and associated prognostic factor analysis.

C. Yu, G. Tao, P. Pan, 2013, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.

B. Nam, H. Kim, J. Lee, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

S. Song, H. Chung, J. Cho, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas.

H. S. Kim, K. Park, S. H. Lee, 1999, Cancer research.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrent chemotherapy for local advanced cervical cancer.

C. Yu, P. Pan, J. Han, 2015, European journal of gynaecological oncology.

Increased long noncoding RNA LINP1 expression and its prognostic significance in human breast cancer.

J. Han, X.-M. Liu, B. Yang, 2018, European review for medical and pharmacological sciences.

Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)

E. Mardis, J. Hoog, R. Aft, 2016 .

Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents.

T. Chou, T C Chou, F A Schmid, 1983, Cancer research.

Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.

H. S. Kim, S. H. Lee, M. Shin, 2001, Cancer research.

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.

Jie Yang, C. Gridelli, M. Ahn, 2022, Clinical lung cancer.